Member Profile

Advagene Biopharma Co., Ltd. is a biopharmaceutical company that aims to develop mucosal immunotherapy, committed to providing human beings around the world the biopharmaceutical development for better epidemic prevention and treatment.
In early 2014, Advagene has completed the licensing of detoxified LT Adjuvant (LTh (αK)) Technology Platform with DCB. This platform can regulate not only humoral but also mucosal immunity and enhance the production of mucosal immunoglobulin A (IgA), which can fortify the efficacy of vaccines and can change the transmission route; such development has high medical potential. Advagene has applied this into the development of nasal influenza vaccine (LT-Flu), respiratory allergy treatment (LT-Allergy), COVID-19 immunotherapy, nasal COVID-19 vaccine and other vaccines, among which LT-Flu nasal flu vaccine phase II clinical trial has been completed at the end of the first season in 2019. LT-Allergy’s phase I/II clinical trial is completed and administered in 2020.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.